New and existing investors in Viela Bio have raised $75m in the latest funding round, allowing the AstraZeneca spin off to progress its NMOSD antibody to regulatory filing in the US. However, established companies may have stolen a march on commercializing a treatment.
The MedImmune LLC spin-out Viela Bio Inc. has raised $75m in a series B financing that it will use to push forward US Food and Drug Administration approval of its monoclonal antibody (MAb) inebilizumab for the rare autoimmune disease neuromyelitis optica spectrum disorder (NMOSD).
Viela presented pivotal data from a Phase IIb study for inebilizumab in January 2019, when analysis demonstrated a 77% reduction...
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
